Icatibant Hikma

Icatibant, the active ingredient in Icatibant Hikma, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with HAE.

GNH USA supplies Icatibant Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Icatibant is used to treat hereditary angioedema, a disorder driven by excessive bradykinin activity.

- Hereditary angioedema type I: provides rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: alleviates symptoms by blocking bradykinin‑mediated vascular leakage. - Hereditary angioedema with normal C1‑INH (HAE‑nC1‑INH): offers symptomatic relief for approved patients experiencing attacks.

Icatibant may cause a range of adverse reactions after subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema unrelated to HAE: unexpected swelling of lips, tongue or airway. - Severe hypotension: marked drop in blood pressure. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count observed in rare cases.

When using Icatibant, several safety considerations should be observed.

- Assess severity of HAE attack: confirm that the episode requires pharmacologic intervention. - Monitor for hypersensitivity: watch for rash, itching, or swelling at the injection site. - Avoid in patients with known hypersensitivity to icatibant or its excipients: discontinue if severe reaction occurs. - Use caution in pregnancy and breastfeeding: safety data are limited; weigh benefits against potential risks. - Evaluate renal and hepatic function: adjust monitoring if organ impairment is present. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or blood pressure.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and reduce the effectiveness of icatibant. - Other bradykinin B2 receptor antagonists: concurrent use can lead to unpredictable pharmacodynamics. - Concomitant use with potent vasodilators: may exacerbate hypotensive effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives or hormone therapy: can increase frequency of HAE attacks, requiring closer observation. - NSAIDs: may aggravate swelling or pain, so monitor patient response.